Искусственные конъюгированные антигены с гаптенами-аналогами психоактивных веществ и токсикантов: алгоритмы моделирования молекулярной структуры гаптенных эпитопов алкалоидов при конструировании иммуногенных антигенов Medline.ru - медико-биологический информационный портал Медлайн.ру

1. Colburn W.A. Radioimmunoassay and related immunoassay techniques. In: Pharmaceutical Analysis Modern Methods, Part A. Munson J.W., ed. New York: Marcel Dekker; 1982.

2. Lee J. W., Colburn W.A. Immunoassay Techniques. In: Ohannesian L. and Streeter A.J., eds. Handbook of Pharmaceutical Analysis. New York - Basel: Marcel Dekker; 2002.

3. Butler V.P, Jr. The immunological assay of drugs. Pharmacol. Rev. 1978; 29(2): 103-184.

4. Ren Z., Zhang H., Wang Z. et al. Progress in immunoassays of toxic alkaloids in plant-derived medicines: A Review. Toxins (Basel). 2022. 14(3): 165; https://doi.org/10.3390/toxins14030165

5. De Weck A.L. Low molecular weight antigens. In: The Antigens, V.2. Sela M., eds. N.Y. - San Francisco - London: Academic Press; 1974: 141-248.

6. Козлов В.К., Беспалов А.Я., Кашуро В.А., Батоцыренова Е.Г. Искусственные конъюгированные антигены с гаптенами-аналогами психоактивных веществ и токсикантов: принципы конструирования и увеличения иммуногенности. Medline.ru. Российский биомедицинский журнал. 2022; 23: 824-855.

7. Козлов В.К., Беспалов А.Я., Кашуро В.А. Искусственные конъюгированные антигены с гаптенами-аналогами психоактивных веществ и токсикантов: общие принципы моделирования специфичности гаптенных эпитопов. Medline.ru. Российский биомедицинский журнал. 2022; 23: 856-901.

8. Козлов В.К., Беспалов А.Я., Гафт С.С. Конъюгаты физиологически активных, токсичных и лекарственных соединений. В кн.: Козлов В.К. и др. Основы иммунотоксикологии. Том 1. Общая иммунотоксикология. Иммунотоксичность химических соединений. Инициируемые токсикантами иммунопатологические состояния и заболевания / под ред. В.К. Козлова. М.: Комментарий; 2019: 364-448.

9. Darwish I.A. Immunoassay methods and their applications in pharmaceutical analysis: Basic methodology and recent advances. Int. J. Biomed. Sci. 2006; 2(3):

217-235.

10. Marks V., Fry D.E. Detection and measurement of drugs in biological fluids: Their relevance to the problem of drug abuse. In: Glatt M.M., ed. Drug Dependence. Dordrecht: Springer; 1977: 295-327. https://doi.org/10.1007/978-94-011-6147-3_13

11. Volkov S.K. Immunoassay of low-molecular-mass physiologically active substances of plant and microbial origin encountered in plants. Russian Chemical Reviews. 1994; 63(1): 91. doi: 10.1070/RC1994v063n01ABEH000073

12. Bremer P.T., Janda K.D. Conjugate vaccine immunotherapy for substance use disorder. Pharmacol. Rev. 2017; 69(3): 298-315. doi.org/10.1124/pr.117.013904

13. Reyes A.Z., Hu K.A., Teperman J. et al. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann. Rheum. Dis. 2021; 80(5):

550-557. doi:10.1136/annrheumdis-2020-219174

14. Tardif J.-Cl., Bouabdallaoui N., L'Allier Ph.L. et al. Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial. The Lancet Resp. Med. 2021; 9(8): 924-932. doi:10.1016/S2213-2600(21)00222-8

15. Pontikis R., Scherrmann J.M., Nguyen H.N. et al. Radioimmunoassay for colchicine: Synthesis and properties of three haptens. J. Immunoassay. 1980; 1(4): 449-461. doi: 10.1080/15321818008056965

16. Sabouraud A., Cano N, Scherrmann J.M. Radioimmunoassay of colchicine with antisera exhibiting variable cross-reactivity. Ther. Drug Monit. 1994; 16(2): 179-185. doi: 10.1097/00007691-199404000-00012

17. Boudene C., Duprey F., Bohuon C. Radioimmunoassay of colchicine. Biochem J. 1975; 151(2): 413-415. doi: 10.1042/bj1510413

18. Rouan S.K., Otterness I., Cunningham A.C., Rhodes C.T. Specific, high affinity colchicine binding monoclonal antibodies: development and characterization of the antibodies. Hybridoma.1989; 8(4): 435-448. doi:10.1089/hyb.1989.8.435

19. Данилова Н.П., Луцкова С.Н., Фадеева И.И. и др. Количественное определение стефарина твердофазным иммуноферментным методом в культуре растительной клетки. Хим.-фарм. журн. 1990; 1: 156-158.

20. Прозоровский В.Б., Донкопий В.Д., Суслова И.М. Взаимодействие обратимых ингибиторов с каталитическими центрами и аллостерическими участками холинэстераз. Бюллетень экспериментальной биологии и медицины. 1976; 82(8): 553-556.

21. Прозоровский В.Б., Павлова Л.В. Суслова И.М. Фармакологическая характеристика нового антихолинэстеразного средства аминостигмина. Экспериментальная и клиническая фармакология. 1992; 55(1): 13-16.

22. Tanahashi T., Poulev A., Zenk M.H. Radioimmunoassay for the quantitative determination of galanthamine. Planta Med. 1990; 56(1): 77-81.

doi: 10.1055/s-2006-960889

23. Poulev A., Deus-Neumann B., Zenk M.H. Enzyme immunoassay for the quantitative determination of galanthamine. Planta Med. 1993; 59(5): 442-446.

doi: 10.1055/s-2006-959728

24. Volkov S.K. Immunoassay of alkaloids. Russ. Chem. Rev. 1993; 62(8): 787-798. doi: 10.1070/RC1993v062n08ABEH000047

25. Кузнецов С.Г., Голиков С.Н. Синтетические атропиноподобные вещества. Л.: Медгиз, 1962; 224 с.

26. Голиков С.Н., Розенгарт В.И. Холинэстеразы и антихолинэстеразные вещества. Л.: Изд-во «Медицина», 1964; 384 с.

27. Fasth A., Sollenberg J., Sorbo B. Production and characterization of antibodies to atropine. Acta Pharm. Suec. 1975; 12(4): 311-322.

28. Berghem L., Bergman U., Schuldt B., Sorbo B. Plasma atropine concentrations dermined by radioimmunoassay after single-dose i.v. and i.m. administration. Br. J. Anaesth. 1980; 52(6): 597-601. doi: 10.1093/bja/52.6.597

29. Wurzburger R., Miller R., Boxenbaum H. et al. Radioimmunoassay of atropine in plasma. J. Pharmacol. Exp. Ther. 1977; 203(2): 435-441.

30. Virtanen R., Kanto J., Iisalo E. Radioimmunoassay for atropine and

l-hyoscyamine. Acta Pharmacol. Toxicol. 1980; 47(3): 208-212. doi: 10.1111/j.1600-0773.1980.tb01561.x

31. Verma P. S. et al. Sensitive radioimmunoassay using antibodies to

l-hyoscyamine: Patent 5,196,351 US, Int. Pat. Cl.2 G01N 33/56. /; No 535190, fill. 09.23.1983; publ. 05.27.1986.

32. Martinsen A., Naaranlahti T., Turkia L. et al. Comparison of radioimmunoassay and capillary gas chromatography in the analysis of l-hyosciamine from plant material. Phytochemical analysis. 1991; 2: 163-166. doi: 10.1002/PCA.2800020404

33. Козлов В.К., Беспалов А.Я., Любимов Ю.А., Гурьянов Г.А., Голиков С.Н. Способ получения эритроцитарного диагностикума для выявления специфических антител (его варианты): Авт. свидетельство СССР 1079247, приор. 8.02.82., регистр. в Гос. реестре изобретений 15.11.83, опубл. 15.03.84, Бюл. 10.

34. Козлов В.К., Беспалов А.Я., Щелканова Л.Б., Гурьянов Г.А. Способ получения конъюгата гаптен-фермент для иммуноферментного анализа: Авт. свидетельство СССР 1351398, приор. 1.09.1984, регистр. в Гос. реестре изобретений 8.07.1987.

35. Weiler E. W., Stockigt J., Zenk M.H. Radioimmunoassay for the quantitative determination of scopolamine. Phytochemistry. 1981; 20(8): 2009-2016.

doi: 10.1016/0031-9422(81)84054-X

36. Hagemann K., Piek K., Stockigt J., Weiler E. W. Monoclonal antibody-based enzyme immunoassay for the quantitative determination of the tropane alkaloid, scopolamine. Planta Med. 1992; 58(1): 68-72. doi: 10.1055/s-2006-961392

37. Kikuchi Y., Irie M., Yoshimatsu K. et al. A monoclonal antibody to scopolamine and its use for competitive enzyme-linked immunosorbent assay. Phytochemistry. 1991; 30(10): 3273-3276. doi: 10.1016/0031-9422(91)83191-m

38. Savary B.J., Dougall D.K. Scopolamine radioimmunoassay for tissue cultures of Datura stramonium. Phytochemistry. 1990; 29(5): 1567-1569.

39. Gable R.S. Comparison of acute lethal toxicity of commonly abused psychoactive substances. Addiction. 2004; 99(6): 686-696. doi: 10.1111/j.1360-0443.2004.00744.x

40. Nutt D.J., King L. A., Phillips L.D. Drug harms in the UK: a multicriteria decision analysis. Lancet. 2010; 376(9752): 1558-1565. doi: https://doi.org/10.1016/S0140-6736(10)61462-6

41. Scholl L., Seth P., Kariisa M. et al. Drug and opioid-involved overdose deaths - United States, 2013-2017. MMWR Morb. Mortal. Wkly Rep. 2019; 67(5152): 1419-1427. doi: 10.15585/mmwr.mm675152e1

42. Van Amsterdam J., Opperhuizen A., Koeter M., Van den Brink W. Ranking the harm of alcohol, tobacco and illicit drugs for the individual and the population. Eur Addict Res. 2010; 16 (4): 202-227. doi: 10.1159/000317249

43. Головко А.И., Ивницкий Ю.Ю., Иванов М.Б., Рейнюк В.Л., Козлов В.К. О биологической активности дизайнерских наркотиков из группы синтетических опиоидов. Успехи современной биологии. 2020; 140(5): 464-477. doi: 10.31857/S0042132420040067

44. Martell B. A., Orson F. M., Poling J. T. et al. Cocaine vaccine for the treatment of cocaine dependence: A randomized double-blind placebo controlled efficacy trial. Arch. Gen Psychiatry. 2009; 66(10): 1116-1123. doi: 10.1001/archgenpsychiatry.2009.128

45. Vasiliu O. Current Trends and perspectives in the immune therapy for substance use disorders. Front Psychiatry. 2022; 13: 882491. doi: 10.3389/fpsyt.2022.882491

46. Celik M. , Fuehrlein B. A review of immunotherapeutic approaches for substance use disorders: Current status and future prospects. Immunotargets Ther. 2022; 11: 55-66. doi: 10.2147/ITT.S370435

47. Scendoni R., Bury E., Ribeiro I.L.A. et al. Vaccines as a preventive tool for substance use disorder: A systematic review including a meta-analysis on nicotine vaccines' immunogenicity. Hum. Vaccin. Immunother. 2022; 18(6): 2140552. doi: 10.1080/21645515.2022.2140552

48. Li F., Cheng K., Antoline J.F. et al. Synthesis and immunological effects of heroin vaccines. Org. Biomol. Chem. 2014; 12(37): 7211-7232. doi: 10.1039/c4ob01053a

49. Simon E. J., Dole W. P., Hiller J. M. Coupling of new active morphine derivative to sepharose for affinity chromatography. Proc. Nat. Acad. Sci. (USA). 1972; 69(7); 1835-1837. doi: 10.1073/pnas.69.7.1835

50. Li Q-Q., Sun C-Y., Luo Y-X. et al. A morphine/heroin vaccine with new hapten design attenuates behavioral effects in rats. J. Neurochem. 2011; 119(6): 1271-1281. doi: 10.1111/j.1471-4159.2011.07502.x

51. Abdel-Monem M.M., Portoghese P.S. N-Demethylathion of morphine and structurally related compounds with chloroformate esters. J. Med. Chem. 1972; 15(2): 208-210. doi: 10.1021/jm00272a025

52. Borowitz I.J., Diakiw V. The preparation and synthetic utility of O-substituted normethylmorphine. J. Het. Chem. 1975; 12: 1123-1126

53. Brine G.A., Boldt K.G., Hart C.K., Carroll F.I. The demethylation of morphine and codeine using methyl chloroformate. Org. Prep. Proceed. Int. 1976; 8(3): 103-106.

54. Usagawa T., Itoh Y., Hifumi E. et al. Characterization of morphine-specific monoclonal antibodies showing minimal cross-reactivity with codeine. J. Immunol. Meth. 1993; 157(1-2): 143-148. doi: 10.1016/0022-1759(93)90080-q

55. Torres O.B., Jatah R., Rice K.C. et al. Caracterization and optimization of heroin hapten-BSA conjugates: method development for the synthesis of reproducible hapten-based vaccines. Anal. Bioanal. Chem. 2014; 406(24): 5927-5937. doi: 10.1007/s00216-014-8035-x

56. Torres O. B., Alving C. R., Matyas G. R. Synthesis of hapten-protein conjugate vaccines with reproducible hapten densities. In: Vaccine Design. Methods and Protocols: Vol. 1: Vaccines for Human Diseases, Thomas S., eds. Methods in Molecular Biology, Vol. 1403. New York: Springer Science+Business Media, 2016; 695-712.

57. Stowe G.N., Vendruscolo L.F., Edwards S. et al. A vaccine strategy that induced propective immunity against heroin. J. Med. Chem. 2011; 54(14): 5195-5204. doi: 10.1021/jm200461m

58. Matyas G. R., Rice K. C., Cheng K. et al. Facial recognition of heroin vaccine opiates: Type 1 crossreactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphine. Vaccine. 2014; 32(13): 1473-1479. doi: 0.1016/j.vaccine.2014.01.028

59. Spector S., Parker C.W. Morphine: radioimmunoassay. Science. 1970; 168 (3937): 1347-1348. doi: 10.1126/science.168.3937.1347

60. Spector S. Quantitative determination of morphine in serum by radioimmunoassay. J. Pharmacol. Exp. Ther. 1971; 178(2): 253-258.

61. Adler F.L., Liu C.T. Detection of morphine by hemagglutination-inhibition. J. Immunol. 1971; 106(6): 1684-1685.

62. Catlin D., Cleeland R., Grunberg E. A sensitive rapid radioimmunoassay for morphine and immunologically related substances in urine and serum. Clin. Chem. 1973; 19(2): 216-220.

63. Laurie D., Manson A.J., Rowell F.J., Seviour J. A rapid, qualitative ELISA test for the specific detection of morphine in serum or urine. Clin. Chim. Acta. 1989; 183(2): 183-195. doi: 10.1016/0009-8981(89)90334-3

64. Colbert D.L., Gallacher G., Ayling P., Turner G.J. Development of fluoroimmunoassays for the specific detection of morphine in urine. Clin. Chim. Acta. 1988; 171(1): 37-48. doi: 10.1016/0009-8981(88)90289-6

65. Glare P.A., Walsh T.D. Clinical pharmacokinetics of morphine. Ther. Drug Monit. 1991; 13(1): 1-23. doi: 10.1097/00007691-199101000-00001

66. Гамалея Н.Б., Берзина А.Г. Вакцины от наркотиков - новое перспективное направление профилактики злоупотребления психоактивными веществами. Наркология. 2011; 10: 70-83.

67. Van Regenmortel M. H. V. From absolute to exquisite specificity. Reflection on the fuzzy nature of speicers, specificity and antigenic sites. J. Immunol. Methods. 1998; 216(1-2): 37-48. doi: 10.1016/s0022-1759(98)00069-6

68. Matyas G.R., Mayorov A.V., Rice K.C. et al. Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine. 2013; 31(26): 2804-2810. doi: 10.1016/j.vaccine.2013.04.027

69. Brinkley M. A brief survey of methods for preparing protein with dyes, haptens and crosslinking reagents. Bioconjugate chemistry. 1992; 3(1): 2-13. doi: 10.1021/bc00013a001

70. Lemus R., Karol M.H. Conjugation of haptens. Methods Mol. Med. 2008;138: 167-182. doi: 10.1007/978-1-59745-366-0_14

71. Yin X.G., Gao X.F., Du J.J. et al. Preparation of protein conjugates via homobifunctional diselenoester cross-Linker. J. Org Lett. 2016; 18 (22): 5796-5799. doi: 10.1021/acs.orglett.6b02568

72. Fujiwara K., Matsumoto N., Masuyama Y. et al. New hapten-protein conjugation method using N-(m-aminobenzoyloxy) succinimide as a two-level heterobifunctional agent: thyrotropin-releasing hormone as a model peptide without free amino or carboxyl groups. J. Immunol. Methods. 1994; 175(1): 123-129. doi: 10.1016/0022-1759(94)90338-7

73. Jourdan P.S., Mansell R.L., Weiler E.W. Radioimmunoassay for the citrus bitter principle, naringin and related flavonoid-7-O-neohesperidosides. Planta Med. 1982; 44(2): 82-86. doi: 10.1055/s-2007-971407

74. Carroll F. I., Blough B. E., Pidaparthi R. R. et al. Synthesis of mercapto-(+)-methamphethamine haptens and their use for obtaining improved epitope dencity on (+)-methamphethamine conjugate vaccines. J. Med. Chem. 2011; 54 (14): 5221-5228. doi: 10.1021/jm2004943

75. Авруцкий Г.Я., Гурович И.Я., Громова В.В. Фармакотерапия психических заболеваний: монография. М.: Медицина; 1974: 472 с.

76. Рохлина М.Х. Клиника наркоманий и токсикоманий. В кн.: Руководство по наркологии / под ред. члена-корр. РАМН, проф. Н. Н. Иванца. М.: Медпрактика-М; 2002: 269-366.

77. Веселовская Н.В., Коваленко А.Е. Наркотики: свойства, действие, фармакокинетика, метаболизм. Пособие для работников наркологических больниц, наркодиспанцеров, химико-токсилогических и судебно-химических лабораторий. М.: Триада-Х, 2000; 196 с.

78. Carrera M.R., Ashley J.A., Parsons I.H. et al. Supression of psychoactive effects of cocaine by active immunization. Nature. 1995; 378(6558): 727-730. doi: 10.1038/378727a0

79. Sakurai M., Wirsching P., Janda K. D. Design and synthesis of a cocaine-diamide hapten for vaccine development. Tetrahedron Letters. 1996; 37: 5479-5482.

80. Carrera M.R., Ashley J.A., Zhou B. et al. Cocaine vaccines: Antibodies protection against relapse in a rat model. Proc. Natl. Acad. Sci. USA. 2000; 97(11): 6202-6206. doi: 10.1073/pnas.97.11.6202

81. Biagini R.E., Klincewicz S.L., Henningsen G.M. et al. Antibodies to morphine in workers exposed to opiates at a narcotics manufacturing facility and evidence for similar antibodies in heroin abusers. Life Sciences. 1990; 47(10): 897-908. doi: 10.1016/0024-3205(90)90604-p

82. Hrafnkelsdottir K., Valgeirsson J., Gizurarson S. Induction of Protective and Specific Antibodies against Cocaine by Intranasal Immunisation Using a Glyceride Adjuvant. Biol. Pharm. Bull. 2005; 28(6): 1038-1042. doi: 10.1248/bpb.28.1038

83. Ramakrishnan M., Kinsey B.M., Singh R.A. et al. Hapten optimization for cocaine vaccine with improved cocaine recognition. Chem. Biol. Drug Des. 2014; 84(3):354-363. doi: 10.1111/cbdd.12326

84. Bloom B.T., Bushell M-J. Vaccines against drug abuse-are we there yet? Vaccines (Basel). 2022; 10(6): 860. doi: 10.3390/vaccines10060860

85. Truong T.T., Kosten T.R. Current status of vaccines for substance use disorders: A brief review of human studies. J. Neurol. Sci. 2022; 434: 120098. doi: 10.1016/j.jns.2021.120098

86. Shen X.Y., Orson F.M., Kosten T.R. Vaccines against drug abuse. Clin. Pharmacol. Ther. 2012; 91: 60-70. doi: 10.1038/clpt.2011.281

87. Hieda Y., Keyler D. E., Vandevoort J. T. et al. Active immunization alters the plasma nicotine concentration in rats. J. Pharm. Exper. Ther. 1997; 283(3): 1076-1081.

88. Hieda Y., Keyler D. E., Ennifar S. et al. Vaccination against nicotine during continued nicotine administration in rats: immunogenicity of the vaccine and effects on nicotine distribution to brain. Int. J. Immunopharmacol. 2000; 22(10): 809-819. doi: 10.1016/s0192-0561(00)00042-4

89. Pentel P.R., Malin D.H., Ennifar S. et al. A nicotine conjugate vaccine reduces nicotine distribution to brain and attenuates its behavioral and cardiovascular effects in rats. Pharmacol. Biochem. Behav. 2000; 65(1):191-198. doi: 10.1016/s0091-3057(99)00206-3

90. Anton B., Leff P. A novel bivalent morphine/heroin vaccine that prevents relapse to heroin addiction in rodents. Vaccine. 2006; 24(16): 3232-3240. doi: 10.1016/j.vaccine.2006.01.047

91. Cerny E.H., Cerny T. Vaccines against nicotine. Human Vaccines. 2009;

5(4): 200-205. doi: 10.4161/hv.5.4.7310

92. McCluskie M.J., Pryde D.C., Gervais D.P. et al. Enhancing immunogenicity of a 3′aminomethylnicotine-DT-conjugate anti-nicotine vaccine with CpG adjuvant in mice and non-human primates. Inter. Immunopharm. 2013; 16(1): 50-56. doi: 10.1016/j.intimp.2013.03.021

93. United Nations Office on Drugs and Crime. World Drug Report 2018 (Set of 5 Booklets); United Nations: San Francisco, CA, USA, 2018. 111.

94. Hossain M.K., Davidson M., Kypreos E., Feehan J., Muir J.A., Nurgali K., Apostolopoulos V. Immunotherapies for the treatment of drug addiction. Vaccines. 2022; 10(11):1778. https://doi.org/10.3390/vaccines10111778 112.